Clinical Trial Update: Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating irinotecan for progressive or recurrent malignant glioma has completed. The trial's status is listed as COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Camptosar (irinotecan)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED